Ozempic subcutaneous injection, Rx only, has not been approved by the FDA as safe and effective to treat obesity and overweight
That small drop of liquid you see on the skin after a rushed injection
No documented serious adverse events in the available research, though long-term human data is still limited
The decision should always weigh patient response , cost, and long-term treatment sustainability
Given the agency's recent history of granting Priority Review to novel obesity agents with breakthrough designation potential, a six-month review clock would place a potential approval in the first half of 2026
These analyses will be framed not as marketing copy but as method-development tools, with clear descriptions of instrument parameters, calibration strategies, and acceptance criteria that experienced analytical scientists can evaluate on their own terms